Crystalline forms of a BACE inhibitor, compositions, and their use
The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.
1. A Crystalline Anhydrous Form 1 of Verubecestat characterized by an X-ray powder diffraction pattern comprising peaks at degrees 2 theta 7.61, 12.48, 13.95, and 15.26 in a X-ray powder diffraction obtained using Cu K alpha radiation.
2. The Crystalline Anhydrous Form 1 of Verubecestat according to claim 1 , wherein the X-ray powder diffraction pattern further comprises diffraction peaks at degrees 2 theta 15.67, 15.91, 16.81, and 17.44.
3. The Crystalline Anhydrous Form 1 of Verubecestat according to claim 2 , wherein the X-ray powder diffraction pattern further comprises diffraction peaks at degrees 2 theta 23.00, 20.73, 26.49, and 25.34.
4. A Crystalline Anhydrous Form 1 of Verubecestat characterized by substantially the same x-ray diffraction pattern as FIG. 1 .
5. A Crystalline Tosylate Form 1 of Verubecestat characterized by an X-ray powder diffraction pattern comprising peaks at degrees 2 theta 6.84, 19.14, 22.28, and 15.78 in a X-ray powder diffraction obtained using Cu K alpha radiation.
6. The Crystalline Tosylate Form 1 of Verubecestat according to claim 5 , wherein the X-ray powder diffraction pattern further comprises diffraction peaks at degrees 2 theta 20.38, 18.04, 17.60, and 14.66.
7. The Crystalline Tosylate Form 1 of Verubecestat according to claim 6 , wherein the X-ray powder diffraction pattern further comprises diffraction peaks at degrees 2 theta 29.84, 27.24, 27.94, and 24.28.
8. A Crystalline Tosylate Form 1 of Verubecestat characterized by substantially the same x-ray diffraction pattern as FIG. 6 .
9. A method of treating an Aβ pathology or one or more symptoms thereof, wherein said Aβ pathology is Alzheimer's disease, olfactory impairment associated with Alzheimer's disease, Down's syndrome, olfactory impairment associated with Down's syndrome, Parkinson's disease, olfactory impairment associated with Parkinson's disease, stroke, microgliosis brain inflammation, pre-senile dementia, senile dementia, progressive supranuclear palsy, cortical basal degeneration, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, mild cognitive impairment, glaucoma, amyloidosis, type II diabetes, diabetes-associated amyloidogenesis, scrapie, bovine spongiform encephalitis, traumatic brain injury, or Creutzfeld-Jakob disease, said method comprising administering a Crystalline Anhydrous Form 1 of Verubecestat according to claim 1 to a person in need thereof in an amount effective to treat said disease or pathology.
10. The method of claim 9 , wherein said Aβ pathology is Alzheimer's disease.
11. The method of claim 9 , wherein said Aβ pathology is mild cognitive impairment.
12. A method of treating an Aβ pathology or one or more symptoms thereof, wherein said Aβ pathology is Alzheimer's disease, olfactory impairment associated with Alzheimer's disease, Down's syndrome, olfactory impairment associated with Down's syndrome, Parkinson's disease, olfactory impairment associated with Parkinson's disease, stroke, microgliosis brain inflammation, pre-senile dementia, senile dementia, progressive supranuclear palsy, cortical basal degeneration, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, mild cognitive impairment, glaucoma, amyloidosis, type II diabetes, diabetes-associated amyloidogenesis, scrapie, bovine spongiform encephalitis, traumatic brain injury, or Creutzfeld-Jakob disease, said method comprising administering a Crystalline Tosylate Form 1 of Verubecestat according to claim 5 to a person in need thereof in an amount effective to treat said disease or pathology.
13. The method of claim 12 , wherein said Aβ pathology is Alzheimer's disease.
14. The method of claim 12 , wherein said Aβ pathology is mild cognitive impairment.